PAREXEL International Corp. has entered into a definitive agreement to acquire The Medical Affairs Company, LLC (TMAC), a provider of outsourced medical affairs services to the pharma/biopharma, and medical device industries. The acquisition is expected to close in February. Financial terms were not disclosed.

TMAC offers strategic and tactical medical science liaison (MSLs) and clinical nurse educator support services, as well as medical affairs consulting, medical communications support, and direct placement services. TMAC is based in Kennesaw, GA, and has approximately 200 U.S.-based employees.

“The commercialization-outsourcing market continues to grow as biopharmaceutical clients increasingly require medical affairs solutions to optimize awareness and understanding of their products in development or already on the market,” said Josef von Rickenbach, chairman and chief executive officer, PAREXEL. “As a company, we are focused on opportunities within commercialization, market access, regulatory, pharmacovigilance, and medical outsourcing. With TMAC, PAREXEL will gain new and distinct medical affairs outsourcing capabilities that will strengthen and expand our commercialization and market access offerings.”

“We are excited to become a part of PAREXEL and offer our clients a comprehensive range of services delivered by a single company. Working together, PAREXEL and TMAC will deliver greater value to clients and meet evolving client needs, throughout the lifecycle of their products,” added Evan Demestihas, MD, RPh, Chief Executive Officer, TMAC.
Following the acquisition, the TMAC management team will remain and continue to manage its employees and the services.